Molecular characteristics of glioblastoma with 1p/19q co-deletion

Brain Tumor Pathology

Volumn 29, Issue 3, 2012, Pages 148-153

  Mizoguchi, Masahiro ^a   Yoshimoto, Koji ^a   Ma, Xinlong ^a   Guan, Yanlei ^a   Hata, Nobuhiro ^a   Amano, Toshiyuki ^a   Nakamizo, Akira ^a   Suzuki, Satoshi O ^a   Iwaki, Toru ^a   Sasaki, Tomio ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

1p 19q co deletion; Glioblastoma; IDH1 2; Olig2; Oligodendroglioma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR SOX2;

CDKN2 GENE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DLL3 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; MOLECULAR PATHOLOGY; MUTATOR GENE; OLIG2 GENE; OLIGODENDROGLIOMA; ONCOGENE; SOX2 GENE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; GENE DELETION; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; NERVE TISSUE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTOME;

EID: 84865237264     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-012-0107-z     Document Type: Conference Paper

References (32)

1. Louis DN, Ohgaki H, Weistler OD et al (2007) WHO Classification of tumours of the central nervous system: International Agency for Research on Cancer (IARC), Lyon
2. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235-2241
3. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473- 1479 (Pubitemid 28482012)
4. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: A molecular reappraisal. Am J Pathol 159:779-786 (Pubitemid 32847166)
5. Cairncross G (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup radiation therapy oncology Group Trial
6. J Clin Oncol 24:2707-2714
7. van den Bent MJ (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715-2722 (Pubitemid 46630567)
8. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861 (Pubitemid 44672036)
9. Griffin CA, Burger P, Morsberger L et al (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65:988-994 (Pubitemid 44521799)
10. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453 (Pubitemid 47339290)
11. Nakamura M, Yang F, Fujisawa H et al (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539-543 (Pubitemid 30368313)
12. Idbaih A, Marie Y, Pierron G et al (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483-487 (Pubitemid 41266639)
13. Hartmann C, Johnk L, Kitange G et al (2002) Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome
14. Cancer Res 62:4100- 4108
15. Mizoguchi M, Betensky RA, Batchelor TT et al (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65:1181-1188 (Pubitemid 44885942)
16. Ducray F, Idbaih A, de Reynies A et al (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Molecular Cancer 7:41
17. Mukasa A, Ueki K, Matsumoto S et al (2002) Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21:3961-3968 (Pubitemid 34679237)
18. Beroukhim R, Getz G, Nghiemphu L et al (2007) Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci 104:20007-20012
19. Vogazianou AP, Chan R, Backlund LM et al (2010) Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. NeuroOncology 12:664- 678
20. Mizoguchi M, Kuga D, Guan Y et al (2011) Loss of heterozygosity analysis in malignant gliomas. Brain Tumor Pathol 28:191-196
21. Yoshimoto K, Iwaki T, Inamura T et al (2002) Multiplexed analysis of post-PCR fluorescence-labeled microsatellite alleles and statistical evaluation of their imbalance in brain tumors. Jpn J Cancer Res 93:284-290 (Pubitemid 34464364)
22. Guan Y, Mizoguchi M, Yoshimoto K et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16:4289-4297
23. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024 (Pubitemid 41609094)
24. Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254
25. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173 (Pubitemid 43357943)
26. Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
27. Miller CR, Dunham CP, Scheithauer BW et al (2006) Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed highgrade gliomas. J Clin Oncol Off J Am Soc Clin Oncol 24:5419- 5426 (Pubitemid 46623175)
28. Pinto LW, Araujo MB, Vettore AL et al (2008) Glioblastomas: Correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Archiv Int J Pathol 452: 481-490
29. Hegi ME, Janzer RC, Lambiv WL et al (2012) Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: Central pathology review of the EORTC-26981/NCIC-CE.3 trial. Acta Neuropathol 123:841- 852
30. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
31. Kuga D, Mizoguchi M, Guan Y et al (2008) Prevalence of copynumber neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. Neuro Oncol 10:995- 1003
32. Mizoguchi M, Nutt CL, Louis DN (2004) Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma. Neurogenetics 5:81-82 (Pubitemid 38297480)